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ABSTRACT Human serum albumin (HSA) is not only a fatty acid and drug carrier protein, it is also a potent inhibitor of Ab self-
association in plasma. However, the mechanism underlying the inhibition of Ab ﬁbrillization by HSA is still not fully understood.
We therefore investigated the Ab-HSA system using a combined experimental strategy based on saturation transfer difference
(STD) NMR and intrinsic albumin ﬂuorescence experiments on three Ab peptides with different aggregation propensities (i.e.,
Ab(12–28), Ab(1–40), and Ab(1–42)). Our data consistently show that albumin selectively binds to cross-b-structured Ab oligo-
mers as opposed to Abmonomers. The HSA/Ab oligomer complexes have KD values in the micromolar to submicromolar range
and compete with the further addition of Ab monomers to the Ab assemblies, thus inhibiting ﬁbril growth (‘‘monomer competitor’’
model). Other putative mechanisms, according to which albumin acts as a ‘‘monomer stabilizer’’ or a ‘‘dissociation catalyst’’, are
not supported by our data, thus resolving previous discrepancies in the literature regarding Ab-HSA interactions. In addition, the
model and the experimental approaches proposed here are anticipated to have broad relevance for the characterization of other
systems that involve amyloidogenic peptides and oligomerization inhibitors.INTRODUCTION
A distinctive hallmark of Alzheimer’s disease (AD) is the
deposition of amyloid plaques in the brain (1). Two major
components of these amyloid deposits are the amyloid-b
(Ab) peptides Ab(1–40) and Ab(1–42) (2). The Ab peptides
are produced through the proteolytic cleavage of the amyloid
precursor protein (APP) (2–4) and are distributed in both the
cerebrospinal fluid (CSF) and blood (5). The brain/blood Ab
equilibrium is shifted toward the bloodstream by agents in
the peripheral serum that do not penetrate the blood–brain
barrier (BBB), but bind the Ab peptide (5). Such agents
have been proposed to act like a ‘‘peripheral sink’’ that
lowers the risk of amyloid plaque deposition in the brain
and consequently the risk of AD (5). One of the most potent
Ab sequestering systems is human serum albumin (HSA),
which under physiological conditions binds >90% of
Ab(1–40) and Ab(1–42) in blood serum (6,7). Furthermore,
HSA is one of the most potent endogenous inhibitors of Ab
fibrillization (6,7). Therefore, the interactions between the
Ab peptides and HSA represent a critical component of the
transport and metabolism of the Ab system, and their inves-
tigation may provide clues for possible therapeutic strategies
against AD.
Despite the physiological and pharmacological relevance
of the Ab/HSA system, the mechanism underlying the inhi-
bition of Ab fibrillization by HSA is still not fully under-
stood. At least three main types of models have been
proposed for proteins known to prevent peptide amyloido-
genesis (Fig. 1, a–c) (8–10). According to model I
(Fig. 1 a), the inhibitory protein (P) selectively binds and
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preventing its self-association. An example of a protein that
acts according to such a ‘‘monomer stabilizer’’ mechanism is
the phage-display selected affibody ZAb3, which binds
monomeric Ab(1–40) with nanomolar affinity, effectively
preventing its fibrillization (8). Another possible mechanism
to explain fibrillization inhibition (model II; Fig. 1 b)
assumes that the oligomers that serve as seeds for rapid
aggregation are kinetically but not thermodynamically stable
(9). In this case, the inhibitory protein P, rather than selec-
tively binding to the monomeric peptide, acts as a catalyst
that accelerates the dissociation of the oligomers into mono-
mers (model II; Fig. 1 b). An example of a system that func-
tions according to such a dissociation catalyst mechanism is
the molecular chaperone Hsp104, which dissociates the olig-
omeric Sup35 prion-peptide into monomeric species that are
unable to interact with Hsp104 (9). An additional model that
does not involve any direct peptide monomer-inhibitory
protein interactions is the ‘‘monomer competitor’’ model
(model III; Fig. 1 c) in which the inhibitory protein selec-
tively binds to the oligomers, preventing the further addition
of peptides and growth into larger oligomer assemblies. An
example of such a mechanism is provided by the apolipopro-
tein E3 (ApoE3), which inhibits fibrillogenesis by binding
soluble oligomers (10). From these examples, it is clear
that different proteins with fibrillization inhibitory functions
often adopt different inhibition mechanisms.
In the case of HSA, based on the data published so far
(6,7,11–14), it is not possible to establish consistently and
conclusively which model best describes its interactions
with the Ab system and the consequent inhibition of Ab
fibrillization. The monomer stabilizer model (model I;
Fig. 1 a) is apparently supported by immunoassays (12)
doi: 10.1016/j.bpj.2009.08.028
2586 Milojevic et al.FIGURE 1 Panels a–c depict pos-
sible hypothetical models for the mech-
anism of oligomerization inhibition by
a generic inhibitory protein P. Ab
denotes the Ab peptide in its mono-
meric state, whereas Abi and Abi’ indi-
cate Ab oligomers. LMW and HMW
Ab refer to low- and high-MW Ab olig-
omers, respectively. The letters n, m,
and n0 refer to integer numbers that
define the stoichiometry of the noncova-
lent complexes involving the Ab
peptide and the P protein. In both
models I and II, oligomers are disrupted
(i.e., ‘‘cleared’’) by P. Whereas an Ab
oligomer-HSA complex in model II
forms only transiently, in model III it
does not clear the oligomers and HSA
binds stably to them, preventing their
further growth into larger assemblies.
To include the possibility that the inhib-
itory binding protein partially converts
large oligomers into a higher number
of smaller oligomers, the subscripts i
and n were replaced by i0 and n0 for
the P-bound oligomers in model III. In
any case, such oligomers must remain
larger than the critical size required to interact with the inhibitory protein (denoted as ics in panel c), i.e., i n ¼ i0 n0 and ics < i0 < i. The cartoon representation
of the models was used for clarity, but it does not imply a specific pathway for fibril formation or assign specific structures or stoichiometries for Ab in differ-
ent oligomerization or HSA-bound states. Panel d summarizes the experimental design to test models I–III. The STD NMR experiments mainly probe
interactions with the low-MW components of the system (i.e., Ab monomers); however, tryptophan fluorescence can probe HSA interactions with both
Ab monomers and oligomers. Due to HSA-ThT interactions, ThT fluorescence can be used to reliably probe cross-b-structured oligomers only in the absence
of HSA.and by circular dichroism (CD) binding studies (13) that
have been interpreted in terms of an Ab monomer:HSA
complex with a 1:1 stoichiometry and a dissociation constant
in the micromolar range (KD ¼ 5 5 1 mM) (12,13).
However, these results do not agree with surface plasmon
resonance (SPR) data (7) showing that albumin interferes
with the incorporation of biotin-Ab(1–40) into amyloid
fibrils by selectively binding polymeric but not monomeric
derivatized Ab(1–40). The SPR evidence therefore does
not support model I. Although similar conclusions were
also obtained through preliminary NMR HSA-binding
studies on a short Ab fragment (11), those early SPR/
NMR results were later dismissed by others (13) on the basis
of the extensive use of derivatization or fragmentation of the
Ab peptides.
Considering the discrepancies currently present in the
literature regarding Ab-HSA interactions (6,7,11–14), it is
important to obtain more direct and conclusive evidence to
reliably establish which model (Fig. 1, a–c) best explains
the inhibitory action of HSA with respect to Ab fibrillization.
In an attempt to solve these inconsistencies, dynamic light
scattering (DLS) was recently employed to map the effect
of bovine serum albumin (BSA) on the oligomer size distri-
bution of Ab(1–40), and the results revealed that albumin
shifts the Ab oligomer distribution toward low-molecular
weight (MW) oligomers and possibly monomers (14).
Biophysical Journal 97(9) 2585–2594However, no conclusive model selection (Fig. 1, a–c) could
be established based on this DLS investigation, because
interactions of albumin with monomeric Ab could not be
ruled out (14).
Given the incongruities among previous reports (6,7,
11–14), our main goal in this study was to differentiate
and clarify which of the three hypothetical mechanisms
(Fig. 1, a–c) applies to the inhibitory function of Ab fibrilli-
zation by HSA. For that purpose, we investigated the HSA/
Ab system using NMR and tryptophan fluorescence, as illus-
trated in Fig. 1 d. These two spectroscopic techniques were
chosen because they probe the multiple interactions of the
HSA/Ab system in complementary ways. NMR is ideal for
sensing interactions involving low-MW species, i.e., mainly
the Ab monomer/HSA and the Ab monomer/Ab oligomer
interactions (Fig. 1 d), whereas fluorescence takes advantage
of the presence of a tryptophan residue in HSA (i.e., W214)
but not in the Ab peptide. As a result, tryptophan fluores-
cence probes only the interactions involving HSA, i.e., the
Ab monomer/HSA and Ab oligomer/HSA interactions
(Fig. 1 d). Thus, all possible interactions of the HSA/Ab
system are detected by this integrated experimental design,
and specifically the putative binding of Ab monomers by
HSA is characterized by two independent methods, pro-
viding a solid experimental basis for the selection of the
hypothetical models outlined in Fig. 1, a–c.
HSA-Ab Interactions 2587The experimental scheme illustrated in Fig. 1 d was
applied to three different Ab peptides with increasing length
and propensity to oligomerize: Ab(12–28), Ab(1–40), and
Ab(1–42). The Ab(12–28) fragment was chosen because it
spans the central hydrophobic core of the Ab peptide and
contains key residues necessary for interactions with HSA
(11). Furthermore, the Ab(12–28) peptide can be easily
stabilized for weeks or months in its monomeric state at
high concentrations suitable for NMR (11,15). In addition,
once Ab(12–28) oligomers form, their exchange with the
monomeric state is sufficiently fast to be detected by satura-
tion transfer difference (STD) NMR experiments with high
sensitivity (11,16). However, Ab(12–28) is only a fragment
of the Ab peptide most commonly found in amyloid plaques
in vivo. We therefore complemented our Ab(12–28) studies
with a parallel investigation on the more biologically rele-
vant Ab(1–40), for which the monomer-to-oligomer transi-
tion is sufficiently slow under conditions suitable for NMR
to allow the acquisition of NMR data for the monomeric state.
Finally, the Ab(1–42) was selected for its high propensity to
self-associate, thus facilitating the detection and characteriza-
tion of interactions involving the Ab oligomers. For each Ab
system, the presence of oligomers was independently
monitored through STD NMR and thioflavin T (ThT) fluores-
cence experiments, thus providing a solid foundation for the
selection of the inhibitory model (Fig. 1, a–c).
For all three tested peptides, our results consistently
support a selective interaction of HSA with Ab oligomers
rather than monomers, which firmly disproves that HSA
acts as a ‘‘monomer stabilizer,’’ i.e., model I in Fig. 1 a is
excluded. Additionally, our data conclusively rule out the
oligomer ‘‘dissociation catalyst’’ model (model II; Fig. 1 b)
and confirm the ‘‘monomer competitor’’ mechanism (model
III; Fig. 1 c). According to this model, HSA binds Ab olig-
omers without causing their full dissociation into monomers,
and competes with the addition of further Ab monomers,
effectively preventing the growth of the Ab oligomers into
larger assemblies.
MATERIALS AND METHODS
Sample preparation
Details about the sample preparation protocols (11,16,17) are available in
the Supporting Material.
NMR spectroscopy
The frequency for the saturation of HSA was optimized using a 0.5 mM
HSA solution prepared in 50 mM acetic acid-d4 at pH 4.7, 10% D2O, and
by setting the carrier frequency of the saturating Gaussian pulse train at
-0.26, 0.57, 0.66, and 7.05 ppm while the off-resonance saturation frequency
was kept constant at 30 ppm. All STD experiments were acquired using
previously described pulse sequences (16,18) and a Bruker Avance
700 MHz spectrometer equipped with 5 mm TCI Cyroprobe (Karlsruhe,
Germany) at 20C, unless otherwise specified. Selective saturation was
achieved using a train of 40 Gaussian-shaped pulses of 50 ms each and sepa-
rated by a 1 ms interpulse delay, resulting in a total saturation time of ~2 s,which was preceded by a 100 ms interscan delay. The strength of each satu-
rating Gaussian pulse was 110 Hz with a 1% truncation and 1000 digitiza-
tion points. The STD spectra were obtained by subtracting on-resonance and
off-resonance spectra through phase cycling, and the off-resonance spectra
were recorded as reference. A 0.1 ms or 30 ms spin lock (SL) was used
before signal detection to respectively maximize or suppress the HSA signal.
For all STR and STD spectra acquired in the presence of an Ab peptide, the
SL duration was set to 30 ms. In all experiments, the water magnetization
was suppressed using the 3-9-19 Watergate gradient spin echo (19). For
all STD experiments, 64 scans and 16 dummy scans were acquired, except
for Ab(1–40) and Ab(1–42), for which 512 scans were accumulated. For the
more sensitive saturation transfer reference (STR) experiments, 32 scans and
32 dummy scans were acquired. The spectral processing parameters are
included in the figure captions. The methyl spectral region (0.6–1.1 ppm)
was integrated and measured as a function of time to monitor the aggregation
profile of the Ab peptides. The error was estimated from the spectral noise to
be ~5%. The one-dimensional (1D) intensity loss was modeled through an
offset-exponential: a  e-bt þ c, where the a–c parameters were obtained
through nonlinear curve-fitting.
Fluorescence spectroscopy
Tryptophan fluorescence spectra were acquired using a Varian Cary Eclipse
spectrophotometer (Mulgrave, Australia) and recorded in a 0.5  1-cm cell
(0.5 cm at the emission and 1 cm at the excitation side) with the excitation
and the emission slit width set to 5 nm. An excitation wavelength of
295 nm was used to excite the single tryptophan residue of HSA, Trp-214
(20–22). When fluorescence measurements were used to investigate ligand
interactions, spectra for recorded ligand solutions without HSA (blank solu-
tions) were acquired first and then subtracted from the spectra in the presence
of HSA. All spectra were recorded three times and smoothed using a 10-point
average. ThT fluorescence spectra were recorded using a Tecan Safire fluores-
cence spectrometer and 96-well plates with 50 mL sample volumes. In this
case, excitation and emission wavelengths were set at 450 and 490 nm, respec-
tively (23). Spectra measured before the addition of 20 mM of ThT were sub-
tracted to correct for the blank fluorescence contribution. For each sample, at
least four measurements were performed and the resulting averaged values are
reported. The error was calculated as the standard deviation of all measure-
ments.
RESULTS
Optimization and controls of STD experiments
A critical step in obtaining a reliable selection among the
models outlined in Fig. 1, a–c is to test whether monomeric
Ab peptides interact with albumin. For this purpose, we used
1D STD and reference (STR) NMR spectra, which are ideal
for probing interactions with KD values in the micromolar
range (24), such as those previously observed between Ab
and HSA (13). In contrast to previous investigations (11),
the STD experiments used here were specifically optimized
to probe Ab-HSA interactions. Details about the optimiza-
tion of the STD experiments and the related controls using
known HSA ligands, such as aspirin and L-tryptophan
(25,26), are provided in Fig. S1, Fig. S2, and Fig. S3.
HSA does not interact with the monomeric
Ab(12–28) peptide
As the initial step in testing model I (Fig. 1 a), we charac-
terized the interactions between HSA and monomeric
Biophysical Journal 97(9) 2585–2594
2588 Milojevic et al.FIGURE 2 (a–d) Effects of HSA on
the STR and STD spectra of 0.2 mM
Ab(12–28) in 50 mM acetic acid-d4,
pH 4.7, 10% D2O. The STR and STD
spectra of 10 and 100 mM HSA solu-
tions were subtracted from the protein
peptide mixture spectra to remove
residual HSA signal. All spectra were
acquired at 700 MHz using a TCI Cryo-
Probe and at 20C. A 30-ms-long SL
was used to minimize the residual
HSA signal. All spectra were processed
using a line-broadening factor of 3 Hz.
Panels e and f depict the effects of
aspirin and Ab(12–28), respectively,
on the emission intrinsic fluorescence
spectra of HSA.Ab(12–28) through STD NMR experiments. Specifically,
we recorded STD data for the Ab(12–28) peptide (Fig. 2,
a–d) using the same acetate buffer and concentrations as in
the control spectra with aspirin and L-tryptophan (Fig. S2).
Under these experimental conditions, Ab(12–28) is stable
as a monomeric species due to the combination of 30 kDa-
cutoff filtration and the subsequent dilution to submillimolar
levels included in our sample preparation protocols (11,
15–17). The absence of oligomers in the Ab(12–28) solu-
tions used for the STD experiments is also independently
confirmed by the lack of STD signal observed in the absence
of HSA (Fig. 2 a), because the 0.66 ppm saturation
frequency employed for albumin causes saturation of the
methyls of Ab(12–28) as well (16). Therefore, if Ab(12–
28) oligomers were present, they would give rise to a detect-
able STD signal in Fig. 2 a, as the monomer/oligomer
exchange in acetate buffer has been shown to be sufficiently
fast to provide excellent saturation transfer (11,16).
It should also be noted that HSA is known to undergo
several pH-dependent interdomain reorientations (22), which
may affect its ligand interactions (25). The different HSA
conformers can be probed using the maximum fluorescence
emission wavelength (lmax), as shown in Fig. S3. Fig. S3
indicates that even at pH 4.7, albumin exists mainly in the
physiological N-state. The STD data of Fig. 2 are therefore
relevant for the N-form of albumin.
The STD and STR data of Fig. 2, b–d, show no significant
STD signal or STR line-broadening for Ab(12–28) at any
HSA concentration tested. The absence of STD signal and
STR line-broadening in Fig. 2, b–d clearly rules out the
possibility that the N-state of HSA interacts with the mono-
meric Ab(12–28) peptide with a KD in the micromolar to
Biophysical Journal 97(9) 2585–2594submillimolar range. It is also highly unlikely that mono-
meric Ab(12–28) binds HSA with a lower KD value (i.e.,
KD ~ nM), as these high-affinity interactions would result
in significant signal losses and/or chemical shift changes in
the reference spectrum of Fig. 2 d.
The NMR results for the Ab(12–28)/HSA system were
further supported by independent HSA tryptophan fluores-
cence experiments. Although wild-type Ab peptides do not
contain Trp residues, a single tryptophan is present in HSA
(i.e., Trp-214) and is located in the proximity of Sudlow
site I in subdomain IIA (26). Quenching of the intrinsic
Trp-214 fluorescence was previously used to probe binding
to HSA for several ligands (26). In general, ligand-dependent
intrinsic tryptophan fluorescence quenching is either due to
direct energy transfer from the albumin fluorophore to the
bound ligand fluorophores or due to ligand-induced varia-
tions in the local Trp environment (20,21,26). For instance,
Fig. 2 e indicates that a significant dose-dependent quench-
ing of the HSA Trp-214 fluorescence occurs upon addition
of aspirin in the 5–25 mM concentration range. Considering
that aspirin, similarly to the Ab peptide, does not absorb at
the HSA emission wavelength region around 340 nm (27),
the data of Fig. 2 e suggest that aspirin perturbs the albumin
structure around Trp-214, as also expected since aspirin
binds to Sudlow site I in the proximity of Trp-214. However,
when similar fluorescence experiments were performed with
the Ab(12–28) peptide prepared in the monomeric state, no
significant Trp fluorescence quenching was observed
(Fig. 2 f), indicating that monomeric Ab(12–28) does not
affect the environment of Trp-214 in HSA, consistent with
the absence of binding as supported by the previous NMR
data (Fig. 2, e–d).
HSA-Ab Interactions 2589FIGURE 3 Effect of HSA on the
STR and STD spectra of Ab(1–40)
and Ab(1–42) samples. All peptide
solutions were prepared at a 0.1 mM
concentration in 20 mM potassium
phosphate buffer, pH 7.4, 10% D2O.
A 30-ms-long SL was used to minimize
the HSA signal. The STR and STD
spectra of the 10 and 100 mM HSA
solutions were collected and then sub-
tracted from the protein peptide mixture
spectra. Although this subtraction was
possible for the 100 mM Ab(1–42)
sample, it was not viable for the
Ab(1–40) sample due to the negligible
STD effect arising from this peptide as
compared to that originating from
albumin. All spectra were acquired at
700 MHz using a TCI CryoProbe and
at 20C. The STR and STD spectra
were processed using a line-broadening
factor of 10 Hz. In panel f, at a 100 mM
albumin concentration, the 30-ms SL
becomes less effective at completely
removing the protein signal, resulting
in residual difference artifacts at a range
of 7.4–7.8 ppm.HSA does not interact with the monomeric
Ab(1–40) peptide
For the purpose of verifying that the absence of interactions
between HSA and Ab(12–28) is not due to the fragmentation
of the Ab peptide, a similar combined NMR and fluores-
cence-based experimental strategy was further extended to
the biologically relevant Ab(1–40) peptide prepared under
conditions that favor the monomeric state (Figs. 3, a–c,
and 4, a and b). Specifically, Ab(1–40) samples with concen-
trations %100 mM and freshly prepared according to the
protocols described in the Supporting Material are largely
monomeric due to the lag time of the nucleation phase in
the aggregation of Ab(1–40) (28). This is also independently
confirmed by ThT fluorescence, which does not detect any
significant concentration of cross-b aggregates for 25 or
100 mM Ab(1–40) (Fig. 4 a), and by the lack of detectable
STD signal for Ab(1–40) alone (Fig. 3 a). Considering, as
discussed above, that the 0.66 ppm irradiation frequency
causes saturation of the Ab methyls as well, the observation
of no significant STD signal in Fig. 3 a points to the absence
of Ab(1–40) oligomers for which the peptide exchange with
the monomeric state occurs sufficiently fast to give rise to
saturation transfer (ST) (16), confirming the monomeric
nature of our 100 mM Ab(1–40) sample. The lack of detect-
able STD signal for Ab(1–40) in Fig. 3 a also indicates that
the Ab(1–40) monomers are sufficiently unstructured to
quench possible intramonomer cross-saturation effects (16).
The STR spectra of freshly prepared 100 mM Ab(1–40) in
the absence and presence of different concentrations of HSA
(Fig. 3, a–c) show no significant changes in line-broadening,chemical shift, or intensity upon addition of HSA to the
peptide solution, pointing to the absence of HSA-monomeric
Ab(1–40) interactions in the micromolar KD range. This
conclusion is further confirmed by the lack of signal in the
STD spectrum of Fig. 3 b and by the absence of significant
variations in the HSA Trp fluorescence spectra acquired
even with 10-fold excess of Ab(140) (Fig. 4 b), further
confirming the absence of interactions in the micromolar
affinity range between HSA and monomeric Ab (1–40).
HSA selectively interacts with the oligomeric
but not the monomeric Ab(1–42)
At a peptide concentration of 25 mM, and using sample prep-
aration protocols that minimize self-association (28), it is
possible to obtain Ab(1–42) solutions for which the ThT
fluorescence is reduced close to basal levels (Fig. 4 a),
suggesting the absence of significant amounts of cross-b-
structured aggregates (29). Under these conditions, no appre-
ciable quenching of the intrinsic albumin fluorescence is
observed upon addition of Ab(1–42) (Fig. 4 c), which is
consistent with the absence of interactions between HSA
and monomeric Ab(1–42) with a KD in the micromolar
range. However, when the self-assembly of Ab(1–42) is
promoted by increasing its concentration to 100 mM, not
only is significant ThT binding observed (Fig. 4 a), pointing
to the presence of assemblies with cross-b structure (29), but
also the intrinsic albumin fluorescence is quenched (Fig. 4 c),
suggesting that albumin selectively binds oligomeric
Ab(1–42) species. A positive control of these results is
provided by a 100 mM Ab(1–42) sample that was further
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measurements and adding HSA. This sample showed
increased ThT fluorescence (Fig. 4 a) and also resulted in
an additional quenching of the HSA intrinsic fluorescence
FIGURE 4 (a) Probing Ab assemblies using ThT fluorescence. All
samples were freshly prepared, with the exception of one 100 mM Ab(1–42)
sample (blue bar) that was aggregated for 3 h at 37C before the ThT fluo-
rescence measurements. This sample is denoted by an asterisk (*). ThT was
present in all samples at a 20 mM concentration. At least four measurements
were collected for each sample, and the average values are reported. The
error was calculated as the standard deviation of all measurements. (b) Inter-
actions of HSA with Ab(1–40) as probed by tryptophan fluorescence. (c)
Interaction of HSA with Ab(1–42) probed by HSA tryptophan fluorescence
quenching at increasing Ab(1–42) concentrations.Biophysical Journal 97(9) 2585–2594(Fig. 4 c), confirming that HSA selectively targets oligomers
with cross-b structures as opposed to monomers.
As a further control for the absence of HSA-Ab(1–42)
interactions, the STD and STR spectra of freshly prepared
100 mM Ab(1–42) were acquired in both the absence and
presence of increasing concentrations of albumin (Fig. 3,
d–f). As shown in Fig. 3, d–f, no significant change is
observed in the STR spectra of Ab(1–42) upon addition of
HSA up to a 1:1 stoichiometric ratio, confirming that
albumin does not bind monomeric Ab(1–42) in the micro-
molar or submillimolar range. In addition, it is interesting
to note that, unlike Ab(1–40) (Fig. 3 a), Ab(1–42) gives
rise to a significant STD signal even in the absence of
albumin (Fig. 3 d). This observation is consistent with intra-
monomer cross-saturation caused by at least partial struc-
turing of the monomeric Ab(1–42) peptide and/or with the
presence of oligomers that are sufficiently small to give
rise to a detectable NMR signal or are in fast/intermediate
exchange with the monomeric state. In either case, these
oligomers are likely occurring early in the fibrillization path-
ways. The absence of STD changes upon albumin addition
(Fig. 3, d–f) is therefore consistent with a selective interac-
tion of HSA with larger assemblies, such as those detected
by ThT fluorescence but not STD, as their exchange with
the monomeric state is too slow and/or their concentration
is too low to be sensed by STR/STD NMR. However,
when we compare ThT and STD as oligomer detection
methods, we should also consider that, unlike STD, the
usefulness of ThT fluorescence measurements for probing
the presence of assemblies with cross-b structure is mainly
limited to Ab solutions without any albumin. This is because
ThT interacts with albumin, as proven by the STD spectra in
Fig. S4. In addition, recent independent studies also reported
that ThT binds albumin with a KD of ~10 mM (30). Such
ThT-albumin interactions may therefore affect and bias
experiments in which ThT fluorescence is employed to
monitor Ab aggregation in the presence of albumin, as
previously attempted (14).
Albumin inhibits Ab(1–42) ﬁbril growth
at substoichiometric concentrations
The analysis presented above clearly shows that HSA targets
Ab oligomers rather than monomers as entailed by models II
and III (Fig. 1, a–c); however, a better differentiation
between these two remaining putative mechanisms requires
additional experiments. For this purpose, we measured the
effect of HSA on the self-association of the Ab(1–42)
peptide at 37C, as monitored through 1D NMR signal losses
over a period of 23 h (Fig. 5 a). Fig. 5 a shows that in the
absence of oligomerization inhibitors, >50% of the original
1D signal is already lost 3 h after the acquisition of the first
1D NMR spectrum. After this rapid initial NMR signal
loss, a slower decay is observed that levels off at a plateau
of ~22–25% of the original 1D intensity (Fig. 5 a). No
HSA-Ab Interactions 2591detectable line-broadening was observed in the NMR spectra
of Ab(1–42) during the course of its aggregation (Fig. 6),
indicating that the exchange beteween NMR-detectable
and NMR-undetectable species of Ab(1–42) is slow on the
chemical shift timescale (> ms). The absence of line-broad-
ening over time also indicates that the observed NMR signal
loss is due to the sequestration of Ab(1–42) monomers into
NMR undetectable oligomers, protofibrils, and fibrils.
In the presence of HSA at substoichiometric ratios (i.e.,
18/1 ¼ [Ab(1–42)]/[HSA]), the overall loss of the peptide
NMR signal over time is significantly reduced relative to
what was observed for Ab(1–42) alone (Fig. 5 a). In the pres-
ence of albumin, the plateau value reached after the initial
rapid decay stabilizes at ~50–60% of the original NMR inten-
sity, i.e., at approximately twice the NMR signal intensity
FIGURE 5 Time-dependent aggregation of 90 mM Ab(1–42) in the
absence (gray curve) and presence (black curve) of 5 mM HSA as monitored
by NMR 1D NMR spectra with a 30-ms SL filter (a) and by intrinsic HSA
tryptophan fluorescence (b). The experimental data were fitted using the
offset decaying exponential: a  e-bt þ c, where t is in hours and the a–c
parameters were obtained through nonlinear curve-fitting. The actual exper-
imental data are plotted in solid circles, and the fitted values are shown in
open circles. Between the readings, samples were incubated in a water
bath at 37C. The NMR intensities reported in panel a are normalized inten-
sities of the methyl spectral region (0.6–1.1 ppm) measured as a function of
time. The error was estimated from the spectral noise to be ~5%. NMR
experiments were acquired at 700 MHz at 37C in 20 mM potassium phos-
phate, pH 7.4, 10% D2O, 0.02% NaN3.detected in the absence of albumin. Since no direct contribu-
tion from the NMR resonances of albumin is expected in these
spectra due to the low protein concentration, as well as the 30-
ms SL filter employed for these 1D spectra, the NMR data in
Fig. 5 a demonstrate that substoichiometric concentrations of
albumin are sufficient to inhibit the transition of Ab(1–42)
from NMR-detectable monomeric species into large, NMR-
undetectable assemblies. Of interest, line-fitting with an
offset-exponential decay function (Fig. 5 a) shows that,
unlike the plateau value, the initial rate of decay is not
dramatically affected by albumin (i.e., 0.37 h1 and
0.32 h1 in the absence and presence of HSA, respec-
tively). Assuming that the initial decay rate senses mostly the
prenuclear early-oligomer seeded self-association, whereas
the plateau height mainly probes the residual monomers or
NMR-detectable oligomers in equilibrium with fibrils, proto-
fibrils, and large oligomers, the data of Fig. 5 a support the
conclusion that HSA targets mainly larger oligomers, in line
with our fluorescence and STD results (Figs. 3 and 4).
The partial aggregation of Ab(1–42) in the presence of
HSA was also monitored through albumin intrinsic Trp
FIGURE 6 Effect of a delayed addition of HSA on the aggregation profile
of Ab(1–42). Panels a and b show the 1D NMR spectra of 90 mM Ab(1–42)
immediately after preparation and after 3 h, respectively. In the absence of
HSA, 2 days after the sample was prepared, ~80% of the initial NMR signal
is lost, as shown in panel c. However, when 10 mM of HSA were added 3 h
after sample preparation, no NMR signal losses were observed even after 2
days (d). These spectra were recorded at 600 MHz and 37C. In between
acquisition sessions, samples were stored in a water bath at 37C. Note
that the Ab(1–42) samples used here and in Fig. 5 came from different stock
solutions.Biophysical Journal 97(9) 2585–2594
2592 Milojevic et al.fluorescence spectra (Fig. 5 b) acquired in parallel with the
NMR data of Fig. 5 a and under experimental conditions
similar to those used for the NMR experiments. The fluores-
cence data of Fig. 5 b show that a significant quenching
occurs for all time points sampled after the addition of
90 mM Ab(1–42). This is because at these concentrations,
samples of freshly prepared Ab(1–42) peptide already
contain significant amounts of aggregates with cross-b struc-
ture, as indicated by the previous ThT fluorescence data
(Fig. 4 a). Overall, Fig. 5 shows that albumin is able to
inhibit the time-dependent shift of the Ab(1–42) oligomer
distribution toward high-MW assemblies (Fig. 5 a) by
binding to cross-b-structured aggregates (Fig. 5 b). This
figure also illustrates the complementarity of NMR and fluo-
rescence experiments. NMR reports mainly on the low-MW
Ab species in solution, which are unlikely to interact directly
with albumin, and therefore the intensity of the first point in
Fig. 5 a is not affected by the addition of HSA. Conversely,
the intrinsic albumin fluorescence also senses interactions
with high-MW Ab oligomers that would otherwise escape
detection by NMR. This is why in Fig. 5 b, the major varia-
tion of Trp fluorescence is observed for the very first time
point, unlike what is observed for the NMR time profile of
Fig. 5 a.
Albumin does not cause the dissociation of Ab
oligomers into monomers
The picture emerging from the data presented above appears
to be consistent with model III (Fig. 1 c) as opposed to model
II (Fig. 1 b). However, model II (Fig. 1 b), according to
which albumin promotes the dissociation of preexisting olig-
omers, is still able to explain the observed inhibition of Ab
fibrillization at substoichiometric amounts of HSA (Fig. 5 a).
Therefore, before conclusively ruling out model II, we
carried out additional experiments by adding albumin to
solutions in which significant populations of Ab oligomers
were preformed. For instance, Fig. 6 illustrates that 3 h after
preparation of the Ab(1–42) samples, a significant loss of 1D
signal intensity is already observed (Fig. 6, a and b), pointing
to the initial formation of assemblies with sizes beyond the
NMR detection limit. If self-association continues after 3 h
in the absence of inhibitory protein, most of the NMR signal
is lost after 2 days (Fig. 6 c). However, if HSA is added 3 h
after preparation, the intensity of the NMR intensity remains
comparable to that measured before the addition of albumin
(Fig. 6, b and d), without the signal losses observed in the
absence of HSA over the same time span (Fig. 6 c), but
also without regaining the signal measured immediately
after sample preparation (Fig. 6 a). These observations
therefore support the notion that HSA does not cause
the Ab(1–42) oligomers to dissociate into monomers.
Similar results were obtained for the Ab(12–28) peptide,
as indicated in Fig. S5 and Fig. S6 and explained in the
Supporting Material.Biophysical Journal 97(9) 2585–2594DISCUSSION
The data presented here (Figs. 2–5) consistently support the
notion that albumin does not bind Ab peptides that are
predominantly in the monomeric or low-MW oligomeric
states and lack a ThT-binding competent cross-b structure.
This conclusion applies not only to the Ab(12–28) fragment
model system (Fig. 2), but also to the longer Ab(1–40) and
Ab(1–42) peptides (Figs. 3–5), and is supported by both
NMR data and independent HSA intrinsic Trp fluorescence
experiments with an extensive series of positive and negative
controls (Figs. 2–5, and Fig. S1, Fig. S2, Fig. S3, and
Fig. S4). On this basis, it is therefore possible to rule out
that albumin inhibits Ab fibrillization though a ‘‘monomer
stabilizer’’ mechanism (i.e., model I; Fig. 1 a). At this stage,
the ‘‘dissociation catalyst’’ and ‘‘monomer competitor’’
models (models II and III; Fig. 1, b and c, respectively),
which involve interactions with Ab oligomers, appear
more plausible. Indeed, interactions between albumin and
the Ab peptide oligomers with a KD in the micromolar to
submicromolar range are fully supported by the quenching
observed in the HSA intrinsic fluorescence spectra (Figs. 4 c
and 5 b) whenever cross-b-structured Ab aggregates are
present as indicated by detectable levels of ThT fluorescence
(Fig. 4 a). Overall, the quenching of the HSA intrinsic fluo-
rescence observed upon addition of HSA appears strikingly
well correlated with the intensity of the ThT fluorescence de-
tected before HSA addition (Fig. 4), as one would expect if
the HSA binding-competent forms of the Ab peptides are
assemblies with cross-b structure.
Our NMR data for experiments in which albumin was
added to preformed Ab assemblies (Fig. 6 and Fig. S5)
show that the interaction between albumin and the Ab olig-
omers does not cause the dissociation of Ab into monomers,
as predicted by the dissociation catalyst model (model II;
Fig. 1 b), but it inhibits the transition of the Ab oligomer
distribution from monomeric or low-MW species into larger,
NMR-undetectable, fibril-like assemblies that would other-
wise occur in the absence of albumin (Fig. 5 a) (31). This
HSA-dependent accumulation of monomeric and low-MW
Ab oligomers is observed even at substoichiometric (i.e.,
18:1) concentrations of albumin (Fig. 5 a) and it is fully
accounted for by the monomer competitor model (model
III; Fig. 1 c), assuming that HSA interacts with larger Ab
oligomers at the sites where further monomers would other-
wise bind. Typically, the number of such sites of monomer
addition is significantly lower than the number of polypep-
tide chains in an oligomer or fibril, and therefore the binding
of substoichiometric amounts of HSA to cross-b-structured
oligomers is in principle sufficient to inhibit further addition
of the monomers to the growing aggregates, thus preventing
the consequent loss of NMR signal as observed in Fig. 5 a.
For further details about the effect of HSA on the mech-
anism of homogenous nucleation growth, see the Supporting
Material.
HSA-Ab Interactions 2593The monomer competitor model (model III; Fig. 1 c) sup-
ported by our data is consistent with previously published
dynamic light scattering (DLS) (14) and surface plasmon
resonance (SPR) (7) experiments. DLS profiles indicate
that when Ab(1–40) aggregates in the presence of the HSA
homolog BSA, the population of large oligomers (i.e.,
Stokes radius ~ 140 nm) decreases and that of smaller assem-
blies (i.e., Stokes radius% 34 nm) increases, consistent with
the accumulation of low-MW species in the presence of HSA
(Fig. 5 a). However, the DLS experiments alone are not
sufficient to rule out possible Ab monomer-HSA interactions
(14). In this respect, SPR is complementary to DLS. SPR
does not map the oligomer redistribution of the Ab peptide,
but it can probe direct albumin-Ab monomer interactions.
Specifically, SPR did not detect any interactions with HSA
or BSA when monomeric biotin-Ab(1–40) was immobilized
on the sensor chip, whereas when the SPR experiment was
repeated with preformed polymers of Ab(1–42) deposited
through a monoclonal antibody, clear evidence for binding
with a micromolar or higher affinity was obtained (7). These
SPR based results are fully consistent with the selectivity of
HSA for large cross-b-structured Ab assemblies as opposed
to Ab monomers, indicating that the SPR data were not
biased by the derivatization of the Ab peptide with biotin
and/or by the type of chip-anchoring technique used, as
previously speculated (13).
Although our conclusions regarding the monomer com-
petitor model (model III; Fig. 1 c) are consistent with and
supported by previous DLS and SPR results, they do not
agree with previous investigations based on CD spectra
(13) and immunoassays that were interpreted in terms of
binary 1:1 complexes between Ab monomers and HSA
(12). A possible explanation for this discrepancy may lie in
the presence of undetected Ab oligomers in equilibrium
with Ab monomers in the samples used for the CD and
immunoassay experiments. Indeed, the Hill coefficients
reported for the binding of Ab(1–40) to HSA are in the
1.4–1.5 range (13), pointing to a higher cooperativity than
that anticipated based on the formation of 1:1 complexes
between Ab monomers and HSA. Another challenge
encountered when CD experiments are used to monitor
Ab-HSA interactions is the deconvolution of the contribu-
tions to the CD spectra from these two interacting
components due to the poor selectivity of CD for Ab and
HSA. This problem is effectively circumvented by using
either intrinsic Trp fluorescence (since Trp is present only
in HSA and not in the Ab peptides) or T1r-filtered NMR
experiments, where the long (30 ms) SL filters out most
contributions from albumin, while preserving the signal of
the low-MW Ab peptides.
CONCLUSIONS
In this work we characterized Ab-HSA interactions using
a combined experimental strategy based on NMR andintrinsic albumin fluorescence, and applied it to a family of
Ab peptides (Ab(12–28), Ab(1–40), and Ab(1–42)) for
which the oligomeric state was independently assessed by
ThT fluorescence and STD NMR experiments. Based on
our NMR and fluorescence data, and on an extensive series
of positive and negative controls, we show that albumin
selectively binds cross-b-structured Ab assemblies as
opposed to Ab monomers. This binding occurs with a KD
in the micromolar or submicromolar range and competes
with the further growth of the HSA-bound Ab oligomers
through monomer addition. Overall, our data clearly support
a monomer competitor model for the Ab fibrillization inhib-
itor function of HSA, resolving previous discrepancies in the
literature regarding Ab-HSA interactions. Other putative
mechanisms, according to which albumin acts as a monomer
stabilizer or a dissociation catalyst, are not supported by our
data.
The proposed model for the Ab-HSA interactions not only
explains how albumin is able to affect fibrillization, it will
also help elucidate how inhibitory proteins affect the dis-
tribution of toxic soluble oligomers of amyloidogenic
peptides in general, such as the islet amyloid polypeptide
(32). Furthermore, the combined STD NMR/fluorescence
approach presented here is likely to be generally suitable
for the investigation of other systems involving the interac-
tions of amyloidogenic peptides with fibrillization-inhibitory
proteins.
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